{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T13:12:40Z","timestamp":1687612360147},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T00:00:00Z","timestamp":1458691200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1208\/s12248-016-9905-2","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T15:31:23Z","timestamp":1458747083000},"page":"914-922","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib"],"prefix":"10.1208","volume":"18","author":[{"given":"Robert C.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Radivoyevitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,23]]},"reference":[{"key":"9905_CR1","first-page":"1","volume":"1","author":"RC Jackson","year":"2012","unstructured":"Jackson RC. Modelling malignant progression with a finite state machine supports a two checkpoint theory of cancer. Biosci Discov. 2012;1:1\u201310.","journal-title":"Biosci Discov"},{"key":"9905_CR2","doi-asserted-by":"crossref","first-page":"14931","DOI":"10.1073\/pnas.0607006103","volume":"103","author":"F Michor","year":"2006","unstructured":"Michor F, Iwasa Y, Nowak MA. The age incidence of CML can be explained by a one-mutation model. Proc Natl Acad Sci U S A. 2006;103:14931\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9905_CR3","volume-title":"Chronic myeloid leukemia","author":"J Cortes","year":"2007","unstructured":"Cortes J, Deininger M. Chronic myeloid leukemia. New York: Informa; 2007."},{"key":"9905_CR4","doi-asserted-by":"crossref","DOI":"10.3109\/9780203213018","volume-title":"Chronic myeloid leukaemia: biology and treatment","author":"A Carella","year":"2001","unstructured":"Carella A, Daley G, Eaves C, et al. Chronic myeloid leukaemia: biology and treatment. London: Martin Dunitz; 2001."},{"key":"9905_CR5","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","volume":"35","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans. 2007;35:1347\u201351.","journal-title":"Biochem Soc Trans"},{"key":"9905_CR6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"89","author":"K Nieborowska-Skorska","year":"1999","unstructured":"Nieborowska-Skorska K, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT5) activation by BCR-ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR-ABL and is required for leukemogenesis. J Exp Med. 1999;89:1229\u201342.","journal-title":"J Exp Med"},{"key":"9905_CR7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.20062335","volume":"204","author":"RA Etten Van","year":"2007","unstructured":"Van Etten RA. Signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med. 2007;204:461\u20135.","journal-title":"J Exp Med"},{"key":"9905_CR8","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","volume":"65","author":"DE MacCallum","year":"2005","unstructured":"MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 2005;65:5399\u2013407.","journal-title":"Cancer Res"},{"key":"9905_CR9","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/sj.onc.1210979","volume":"27","author":"WJ Tao","year":"2008","unstructured":"Tao WJ, Lin H, Samanta AK, Arlinghaus R. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene. 2008;27:3194\u2013200.","journal-title":"Oncogene"},{"key":"9905_CR10","first-page":"331","volume":"38","author":"J Lee","year":"2008","unstructured":"Lee J, Kim Y, Lim J, Kim M, Han K. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia. Ann Clin Lab Sci. 2008;38:331\u20137.","journal-title":"Ann Clin Lab Sci"},{"key":"9905_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cyto.2013.12.006","volume":"66","author":"FA Zouein","year":"2014","unstructured":"Zouein FA, Duh\u00e9 RJ, Arany I, et al. Loss of STAT3 in mouse embryonic fibroblasts reveals its Janus-like actions on mitochondrial function and cell viability. Cytokine. 2014;66:7\u201316.","journal-title":"Cytokine"},{"key":"9905_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00030","author":"RR Nair","year":"2012","unstructured":"Nair RR, Tolentino JH, Argilagos RF, et al. Role of STAT3 in transformation and drug resistance in CML. Front Oncol. 2012. doi: 10.3389\/fonc.2012.00030 .","journal-title":"Front Oncol"},{"key":"9905_CR13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.leukres.2013.11.012","volume":"38","author":"D Sayed","year":"2014","unstructured":"Sayed D, Badrawy H, Gaber N, Khalaf MR. p-STAT3 and Bcr-Abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy. Leuk Res. 2014;38:243\u201350.","journal-title":"Leuk Res"},{"key":"9905_CR14","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","volume":"119","author":"M Nieborowska-Skorska","year":"2012","unstructured":"Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012;119:4253\u201363.","journal-title":"Blood"},{"key":"9905_CR15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0021-9258(18)48474-8","volume":"267","author":"KC Cheng","year":"1992","unstructured":"Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb L. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G\u2009\u2192\u2009T and A\u2009\u2192\u2009C substitutions. J Biol Chem. 1992;267:166\u201372.","journal-title":"J Biol Chem"},{"key":"9905_CR16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.1964.94","volume":"18","author":"KR Harrap","year":"1964","unstructured":"Harrap KR, Speed DEM. Some biochemical aspects of leukaemias: the appearance of a soluble disulphide in the blood of chronic granulocytic leukaemia. Br J Cancer. 1964;18:809\u201317.","journal-title":"Br J Cancer"},{"key":"9905_CR17","first-page":"1643","volume":"25","author":"F Bergel","year":"1965","unstructured":"Bergel F, Harrap KR. Future possibilities for the development of treatments of leukemia. Cancer Res. 1965;25:1643\u20138.","journal-title":"Cancer Res"},{"key":"9905_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2964(69)90090-5","volume":"5","author":"KR Harrap","year":"1969","unstructured":"Harrap KR, Jackson RC. Some biochemical aspects of leukaemias: leukocyte glutathione metabolism in chronic granulocytic leukaemia. Eur J Cancer. 1969;5:61\u20137.","journal-title":"Eur J Cancer"},{"key":"9905_CR19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"9905_CR20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New Engl J Med. 2006;354:2542\u201351.","journal-title":"New Engl J Med"},{"key":"9905_CR21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","volume":"109","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome\u2013positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;109:497\u20139.","journal-title":"Blood"},{"key":"9905_CR22","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. New Engl J Med. 2012;367:2075\u201388.","journal-title":"New Engl J Med"},{"key":"9905_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of ten years: data from the randomized CML-study IV. Leukemia. 2015. doi: 10.1038\/leu.2015.36 .","journal-title":"Leukemia"},{"key":"9905_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70105-1","author":"JY Blay","year":"2015","unstructured":"Blay JY, Shen L, Rutkowski P, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromas tumors (ENESTg1): a randomized phase 3 trial. Lancet Oncol. 2015. doi: 10.1016\/S1470-2045(15)70105-1 .","journal-title":"Lancet Oncol"},{"key":"9905_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00280-014-2556-z","volume":"74","author":"RC Jackson","year":"2014","unstructured":"Jackson RC, Radivoyevitch T. A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia. Cancer Chemother Pharmacol. 2014;74:765\u201376. doi: 10.1007\/s00280-014-2556-z .","journal-title":"Cancer Chemother Pharmacol"},{"key":"9905_CR26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.leu.2403626","volume":"19","author":"M Jongen-Lavrencic","year":"2005","unstructured":"Jongen-Lavrencic M. Bcr\/Abl-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration towards CCR7 ligands CCL19 and CCL21 in primary Bcr\/Abl-positive cells. Leukemia. 2005;19:373\u201380.","journal-title":"Leukemia"},{"key":"9905_CR27","unstructured":"Malpas JS. Chemotherapy. In Introduction to the cellular and molecular biology of cancer (Franks LM and Teich N, editors.), p.363. Oxford University Press; 1986."},{"key":"9905_CR28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435:1267\u201370.","journal-title":"Nature"},{"key":"9905_CR29","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","volume":"118","author":"M Tang","year":"2011","unstructured":"Tang M, Gonen M, Quintas-Cardama A, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011;118:1622\u201331.","journal-title":"Blood"},{"key":"9905_CR30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s004110050156","volume":"38","author":"T Radivoyevitch","year":"1999","unstructured":"Radivoyevitch T, Ramsey MJ, Tucker JD. Estimation of the target stem-cell population size in chronic myeloid leukemogenesis. Radiat Environ Biophys. 1999;38:201\u20136.","journal-title":"Radiat Environ Biophys"},{"key":"9905_CR31","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-09-381855","volume":"119","author":"T Radivoyevitch","year":"2012","unstructured":"Radivoyevitch T, Hlatky L, Landaw J, Sachs RK. Quantitative modelling of chronic myeloid leukemia: insights from radiobiology. Blood. 2012;119:4363\u201371.","journal-title":"Blood"},{"key":"9905_CR32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0006-3495(76)85772-4","volume":"16","author":"SI Rubinow","year":"1976","unstructured":"Rubinow SI, Lebowitz JL. A mathematical model of the chemotherapeutic treatment of acute myeloblastic leukemia. Biophys J. 1976;16:1257\u201371.","journal-title":"Biophys J"},{"key":"9905_CR33","volume-title":"R Graphics","author":"P Murrell","year":"2006","unstructured":"Murrell P. R Graphics. Boca Raton: Chapman and Hall; 2006."},{"key":"9905_CR34","unstructured":"Radivoyevitch T. http:\/\/epbi-radivot.cwru.edu\/SEERaBOMB\/SEERaBOMB.html ."},{"key":"9905_CR35","unstructured":"National Cancer Institute. Surveillance, epidemiology and end results program. www.seer.cancer.gov\/report_to_nation . (accessed April 20, 2015)."},{"key":"9905_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.7750\/BioDiscovery.2013.7.4","volume":"7","author":"RC Jackson","year":"2013","unstructured":"Jackson RC, Radivoyevitch T. Modelling c-Abl signalling in activated neutrophils: the anti-inflammatory effect of seliciclib. Biosci Discov. 2013;7:4. doi: 10.7750\/BioDiscovery.2013.7.4 .","journal-title":"Biosci Discov"},{"key":"9905_CR37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"9905_CR38","doi-asserted-by":"crossref","unstructured":"Fernandez E, Pang J, Snell C et al. DrugCARD: a database of anticancer treatment regimens and drug combinations. PAGE Meeting (Population Approach Group Europe), Glasgow, Scotland 11\u201314 June 2013.","DOI":"10.1158\/1538-7445.AM2013-5147"},{"key":"9905_CR39","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","volume":"117","author":"H Makishima","year":"2011","unstructured":"Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myeloid leukemia. Blood. 2011;117:e198\u2013206.","journal-title":"Blood"},{"key":"9905_CR40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000092963","volume":"13","author":"P Duesberg","year":"2006","unstructured":"Duesberg P, Li R, Fabarius A, Hehlman R. Aneuploidy and cancer: from correlation to causation. Contrib Microbiol. 2006;13:16\u201344.","journal-title":"Contrib Microbiol"},{"key":"9905_CR41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1083\/jcb.200905057","volume":"188","author":"SL Thompson","year":"2010","unstructured":"Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol. 2010;188:369\u201381.","journal-title":"J Cell Biol"},{"issue":"8","key":"9905_CR42","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"03","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;03(8):2794\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9905_CR43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","volume":"210","author":"S Nanda","year":"2007","unstructured":"Nanda S, Moore H, Lenhart S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci. 2007;210:143\u201356.","journal-title":"Math Biosci"},{"key":"9905_CR44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mbs.2010.06.005","volume":"227","author":"B Ainseba","year":"2010","unstructured":"Ainseba B, Benosman C. Optimal control for resistance and suboptimal response in CML. Math Biosci. 2010;227:81\u201393.","journal-title":"Math Biosci"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-016-9905-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-016-9905-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-016-9905-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T02:06:25Z","timestamp":1655345185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-016-9905-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,23]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["9905"],"URL":"https:\/\/doi.org\/10.1208\/s12248-016-9905-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,23]]}}}